Suppr超能文献

活化的 Akt-mTOR 通路和受体酪氨酸激酶在孤立性纤维性肿瘤患者中。

Activation of the Akt-mTOR pathway and receptor tyrosine kinase in patients with solitary fibrous tumors.

机构信息

Department of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.

出版信息

Cancer. 2014 Mar 15;120(6):864-76. doi: 10.1002/cncr.28506. Epub 2013 Dec 18.

Abstract

BACKGROUND

Solitary fibrous tumors (SFTs) are soft tissue tumors of intermediate malignancy that rarely metastasize. Although unresectable SFTs are reported to have a poor prognosis, to the authors' knowledge there is currently no effective therapy. Molecular target therapy is a promising approach for patients with unresectable tumors, but knowledge of the molecular biology of SFTs is currently insufficient to support such therapy. The current study investigated the activation of receptor tyrosine kinases (RTKs) and the Akt-mammalian target of rapamycin (Akt-mTOR) pathway in SFTs as therapeutic targets.

METHODS

The phosphorylation statuses of Akt-mTOR pathway proteins (p-Akt, p-mTOR, phosphorylated 4E-binding protein [p-4EBP1], and phosphorylated S6 ribosomal protein [p-S6RP]) and RTKs (phosphorylated platelet-derived growth factor receptor-α [p-PDGFRα], p-PDGFRβ, p-c-met, and phosphorylated insulin-like growth factor-1 receptor-β [p-IGF-1Rβ]) were assessed by immunohistochemistry in 66 samples of SFTs, and the data were compared with clinicopathological and histopathological findings. The expression of phosphorylated proteins was assessed by Western blot analysis in 6 frozen samples.

RESULTS

The immunohistochemical results were as follows: p-Akt, 56.0% (nuclear and cytoplasmic staining); p-mTOR, 69.6% (nuclear and cytoplasmic staining); p-4EBP1, 80.3% (nuclear and cytoplasmic staining); p-S6RP, 69.6% (cytoplasmic staining); p-PDGFRα, 39.0% (cytoplasmic staining); p-PDGFRβ, 52.0% (cytoplasmic staining); p-c-met, 37.8% (nuclear staining) and 19.6% (cytoplasmic staining); and p-IGF-1Rβ, 16.6% (nuclear staining). Phosphorylation of the Akt-mTOR pathway proteins was correlated with one another except for p-Akt with S6RP. p-PDGFRβ and p-IGF-1Rβ were correlated with p-Akt. Moreover, significant relationships were noted between disease-free survival or overall survival and the presence of hypoglycemia, necrosis, cystic and myxoid degeneration, and atypical findings.

CONCLUSIONS

The Akt/mTOR pathway was activated in approximately 50% of the cases of SFTs and was associated with RTKs, which were phosphorylated at different rates. Thus, the Akt-mTOR pathway may be involved in the tumorigenesis of SFTs.

摘要

背景

孤立性纤维瘤(SFT)是一种软组织肿瘤,具有中等恶性,很少发生转移。虽然不可切除的 SFT 预后较差,但据作者所知,目前尚无有效的治疗方法。分子靶向治疗是不可切除肿瘤患者的一种有前途的治疗方法,但目前对 SFT 的分子生物学了解不足,无法支持这种治疗。本研究探讨了受体酪氨酸激酶(RTKs)和 Akt-哺乳动物雷帕霉素靶蛋白(Akt-mTOR)通路在 SFT 中的激活作为治疗靶点。

方法

通过免疫组织化学方法检测 66 例 SFT 样本中 Akt-mTOR 通路蛋白(p-Akt、p-mTOR、磷酸化 4E 结合蛋白 [p-4EBP1] 和磷酸化 S6 核糖体蛋白 [p-S6RP])和 RTKs(磷酸化血小板衍生生长因子受体-α [p-PDGFRα]、p-PDGFRβ、p-c-met 和磷酸化胰岛素样生长因子-1 受体-β [p-IGF-1Rβ])的磷酸化状态,并将数据与临床病理和组织病理学发现进行比较。使用 6 个冷冻样本通过 Western blot 分析评估磷酸化蛋白的表达。

结果

免疫组织化学结果如下:p-Akt,56.0%(核和细胞质染色);p-mTOR,69.6%(核和细胞质染色);p-4EBP1,80.3%(核和细胞质染色);p-S6RP,69.6%(细胞质染色);p-PDGFRα,39.0%(细胞质染色);p-PDGFRβ,52.0%(细胞质染色);p-c-met,37.8%(核染色)和 19.6%(细胞质染色);p-IGF-1Rβ,16.6%(核染色)。除了 p-Akt 与 S6RP 之间外,Akt-mTOR 通路蛋白的磷酸化彼此相关。p-PDGFRβ 和 p-IGF-1Rβ 与 p-Akt 相关。此外,无病生存率或总生存率与低血糖、坏死、囊性和黏液样变性以及非典型发现之间存在显著关系。

结论

大约 50%的 SFT 病例中激活了 Akt/mTOR 通路,并且与 RTKs 相关,RTKs 的磷酸化率不同。因此,Akt-mTOR 通路可能参与 SFT 的肿瘤发生。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验